Dexamethasone Use in HIV-1 Infected Patients with TB Meningitis

Evidence-Based Recommendations

The American Thoracic Society and Infectious Diseases Society of America recommend using dexamethasone for tuberculous meningitis in HIV-negative patients, with strong recommendation and moderate certainty evidence 1, 2
The European Respiratory Society warned that corticosteroids should be used with caution in HIV-infected patients in 1999 4

The Centers for Disease Control and Prevention and World Health Organization recommend initiating a 4-drug regimen immediately, consisting of isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampin for 7-10 additional months, for a total of 9-12 months for HIV co-infection 5, 6, 1, 2
Daily dosing is strongly recommended over intermittent regimens by the European Respiratory Society 6
The Infectious Diseases Society of America recommends monitoring cerebrospinal fluid parameters, such as cell count, glucose, and protein, especially during the first weeks of therapy 1, 2
The European Respiratory Society recommends monitoring rifampin blood levels if poor response to treatment occurs, as malabsorption is possible 6

The European Respiratory Society suggests that short-term dexamethasone for acute management of increased intracranial pressure may be warranted based on clinical judgment, though this represents off-protocol use not supported by trial evidence 4
The European Respiratory Society recommends ensuring drug susceptibility testing is performed, as HIV-infected patients with multidrug-resistant tuberculous meningitis have significantly higher mortality, and referring to specialized centers for management if resistance is detected 6